Lupin Pharmaceuticals have announced the re-introduction of Methergine (methylergonovine maleate) Oral Tablets 0.2mg for the prevention and management of postpartum hemorrhage (PPH). Methergine is the only FDA-approved oral uterotonic oral agent available to treat PPH.

According to the Association of Women’s Health Obstetric and Neonatal Nurses (AWHONN), PPH is defined as blood loss in excess of 500mL or 1000mL after vaginal or cesarean delivery, respectively. Previous studies by AWHONN (Practice Brief. Quantification of Blood Loss. JOGNN. 2014:1-3) have highlighted how visual estimation of blood loss is often underestimated for volumes over 1000mL and overestimated for smaller volumes.

RELATED: Antidepressants Exposure Linked to Postpartum Hemorrhage

Methergine is a semi-synthetic ergot alkaloid. It is indicated for routine management of uterine atony, hemorrhage and subinvolution of the uterus, following delivery of the placenta. It is also indicated for control of uterine hemorrhage in the second stage of labor following delivery of the anterior shoulder.  Methergine provides specific and rapid (onset of action under 10 minutes) uterotonic action on the smooth muscle of the uterus to increase contractions, resulting in restricting blood loss.

The product will be available in bottles containing 7, 12, 28, and 100 tablets. 

For more information visit